King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
17:58
The shares of companies on the Bucharest Stock Exchange can be traded through Interactive Brokers.
17:57
Three executions scheduled in a single day in the USA, a premiere after 16 years
17:49
The prices of diesel transport have exceeded the prices of aviation fuel in Europe
17:49
Two women discovered 86,000 euros in an abandoned piece of furniture in Bologna. The money was handed over to the City Hall, and after a year, the women and the heir of the owner reached an agreement regarding the compensation of the amount.
17:43
Japan summoned the Russian ambassador to protest against Vladimir Putin's visit to the Kuril Islands.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
